Kane Biotech (CVE:KNE) Hits New 52-Week Low – Here’s Why

Kane Biotech Inc. (CVE:KNE)’s share price reached a new 52-week low during trading on Wednesday . The company traded as low as C$0.03 and last traded at C$0.03, with a volume of 279000 shares. The stock had previously closed at C$0.04.

Kane Biotech Price Performance

The firm has a 50-day moving average of C$0.04 and a 200 day moving average of C$0.04. The company has a market capitalization of C$5.02 million, a PE ratio of -0.38 and a beta of 0.60. The company has a debt-to-equity ratio of -289.57, a current ratio of 0.90 and a quick ratio of 0.39.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.